Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

142.58 -7.38 (-4.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 208,988
Open 145.32
Bid (Size) 112.91 (100)
Ask (Size) 226.59 (200)
Prev. Close 149.96
Today's Range 139.92 - 148.35
52wk Range 46.08 - 161.38
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands ↗
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN... 
Via MarketBeat
News headline image
Palvella (PVLA) Q2 2026 Earnings Call Transcript ↗
Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy. 
Via The Motley Fool
Topics Earnings

Performance

YTD
+42.2%
+42.2%
1 Month
+14.8%
+14.8%
3 Month
+23.4%
+23.4%
6 Month
+79.1%
+79.1%
1 Year
+194.0%
+194.0%

More News

Read More
News headline image
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗
Via Chartmill
News headline image
Palvella Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call ↗
Via Benzinga
News headline image
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
What is the current price of Palvella Therapeutics, Inc. - Common Stock?
The current price of Palvella Therapeutics, Inc. - Common Stock is 142.58
When was Palvella Therapeutics, Inc. - Common Stock last traded?
The last trade of Palvella Therapeutics, Inc. - Common Stock was at 08/20/26 04:00 PM ET
What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 14.11B
How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
Palvella Therapeutics, Inc. - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.